

- Albers JW, Chaudhry V, Cavaletti G, Donehower RC. Interventions for preventing neuropathy caused by cisplatin and related compounds. *Cochrane Database Syst Rev*. 2014
- Argyriou AA, Bruna J, Marmiroli P, Cavaletti G. Chemotherapy-induced peripheral neurotoxicity (CIPN): An update. *Crit Rev Oncol Hematol*. 2012;82(1):51–77.
- Argyriou AA, Koltzenburg M, Polychronopoulos P, Papapetropoulos S, Kalofonos HP. Peripheral nerve damage associated with administration of taxanes in patients with cancer. *Crit Rev Oncol Hematol*. 2008;66(3):218–28.
- Argyriou AA, Kyritsis AP, Makatsoris T, Kalofonos HP. Chemotherapy-induced peripheral neuropathy in adults: A comprehensive update of the literature. *Cancer Manag Res*. 2014;6:135–147.
- Arrieta O, Ortega RMM, Villanueva-Rodríguez G, Serna-Thomé MG, Flores-Estrada D, Díaz-Romero C, et al. Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxel-cisplatin chemotherapy: a prospective study. *Nutr Cancer*. 2010;62(1):1–7.
- Azoulay D, Giryes S, Nasser R, Sharon R, Horowitz NA. Prediction of chemotherapy-induced peripheral neuropathy in patients with lymphoma and myeloma: the roles of brain-derived neurotropic factor protein levels and a gene polymorphism. *J Clin Neurol*. 2019;15(4):511–6.
- Banach M, Juranek JK, Zygulska AL. Chemotherapy-induced neuropathies—A growing problem for patients and health care providers. *Brain Behav*. 2016;7:e00558.
- Binda D, Cavaletti G, Cornblath DR, Merkies ISJ; CI-PeriNomS Study Group. Rasch-transformed Total Neuropathy Score clinical version (RT-TNSc) in patients with chemotherapy-induced peripheral neuropathy. *J Peripher Nerv Syst*. 2015;20(3):328–332. doi:10.1111/jns.12140.
- Boyette LB, Tuan RS. Adult stem cells and diseases of aging. *J Clin Med*. 2014;3(1):88–134.
- Brown TJ, Sedhom R, Gupta A. Chemotherapy-induced peripheral neuropathy. *JAMA Oncol*. 2019;5(5):750.
- Burgess J, Ferdousi M, Gosal D, Boon C, Matsumoto K, Marshall A, et al. Chemotherapy-Induced Peripheral Neuropathy: Epidemiology, Pathomechanisms and Treatment. *Oncol Ther*. 2021;9(2):385–450.
- Cao W, Shao Y, Zou S, Wang N, Wang J. Prognostic significance of systemic immune-inflammation index in patients with bladder cancer: a systematic review and meta-analysis. *Medicine (Baltimore)*. 2022;101(36):e30380.
- Cavaletti G, Frigeni B, Lanzani F, et al.; Italian NETox Group. The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale. *J Peripher Nerv Syst*. 2007;12(3):210–215.
- Cavaletti G, Frigeni B, Lanzani F, Mattavelli L, Susani E, Alberti P, et al. Chemotherapy-induced peripheral neurotoxicity assessment: a critical revision of the currently available tools. *Eur J Cancer*. 2010;46:479–494.
- Chen L, Kong X, Wang Z, Wang X, Fang Y, Wang J. Pre-treatment systemic immune-inflammation index is a useful prognostic indicator in patients with

- Cheng HW, Wang T, Yu GC, Xie LY, Shi B. Prognostic role of the systemic immune-inflammation index and pan-immune inflammation value for outcomes of breast cancer: a systematic review and meta-analysis. *Eur Rev Med Pharmacol Sci.* 2024;28(1):180–90.
- Chu B, Chen Y, Pan J. Prognostic significance of systemic immune inflammation index for ovarian cancer: an updated systematic review and meta-analysis. *J Ovarian Res.* 2025;18(1):41.
- Cioroiu C, Weimer LH. Update on chemotherapy-induced peripheral neuropathy. *Curr Neurol Neurosci Rep.* 2017;17(6):47.
- Crichton M, Yates PM, Agbejule OA, Spooner A, Chan RJ, Hart NH. Non-pharmacological self-management strategies for CIPN. *Nutrients.* 2022;14(12):2403.
- Dahlan MS. *Besar Sampel Dalam Penelitian Kedokteran dan Kesehatan.* 4th ed. Jakarta: Epidemiologi Indonesia; 2016.
- De Iulius F, Taglieri L, Salerno G, Lanza R, Scarpa S. Taxane induced neuropathy in patients affected by breast cancer: literature review. *Crit Rev Oncol Hematol.* 2015;96(1):34–45.
- Desforges AD, Hebert CM, Spence AL, Reid B, Dhaibar HA, Cruz-Topete D, et al. Treatment and diagnosis of chemotherapy-induced peripheral neuropathy: an update. *Biomed Pharmacother.* 2022;147:112671..
- Dorand RD, Mendiola DP, Thakur SB, et al. Correlates of taxane-induced neuropathy: an electronic health record analysis of 3 387 patients. *Cancers (Basel).* 2023;15(3):754.
- Eckhoff AS, Knoop MB, Jensen M, Ewertz M. Persistence of docetaxel-induced neuropathy and impact on quality of life among breast cancer survivors. *Eur J Cancer.* 2015;51:292–300.
- Ezendam NP, Pijlman B, Bhugwandass C, Pruijt JF, Mols F, Vos MC, et al. Chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer survivors: results from the population-based PROFILES registry. *Gynecol Oncol.* 2014;135(3):510–517.
- Gordon-Williams R, Farquhar-Smith P. Recent advances in understanding chemotherapy-induced peripheral neuropathy. *F1000Res.* 2020;9:177.
- Gornstein EL, Schwarz TL. Neurotoxic mechanisms of paclitaxel are local to the distal axon and independent of transport defects. *Exp Neurol.* 2017;288:153–166.
- Grisold W, Cavaletti G, Windebank AJ. Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. *Neuro Oncol.* 2012;14(Suppl 4):iv45–iv54.
- Gutiérrez-Gutiérrez G, Sereno M, Miralles A, Casado-Sáenz E, Gutiérrez-Rivas E. Chemotherapy-induced peripheral neuropathy: clinical features, diagnosis, prevention and treatment strategies. *Clin Transl Oncol.* 2010;12(2):81–91.
- Han Y, Smith MT. Pathobiology of cancer chemotherapy-induced peripheral neuropathy (CIPN). *Front Pharmacol.* 2013;4:156.
- Hu B, Yang XR, Xu Y, Sun YF, Sun C, Guo W, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. *Cancer Biol Ther.* 2014;15(7):725–732.

- Izycki D, Niezgodą AA, Kazmierczak M, Pierunek T, Izycka N, Karaszewska B, et al. Chemotherapy-induced peripheral neuropathy: diagnosis, evolution and treatment. *Ginekol Pol.* 2016;87(7):516–521.
- Jia W, Wu J, Jia H, Yang Y, Zhang X, Chen K, et al. The peripheral blood neutrophil-to-lymphocyte ratio is superior to the lymphocyte-to-monocyte ratio for predicting the long-term survival of triple-negative breast cancer patients. *PLoS One.* 2015;10(11):e0143061.
- Jiang C, Lu Y, Zhang S, Huang Y. Systemic immune-inflammation index is superior to neutrophil-to-lymphocyte ratio in prognostic assessment of breast cancer patients undergoing neoadjuvant chemotherapy. *Biomed Res Int.* 2020;2020:7961568.
- Jiang L, Fang J, Ding J. High systemic immune-inflammation index predicts poor survival in patients with HER2-positive breast cancer receiving adjuvant trastuzumab. *Cancer Manag Res.* 2020;12:475–484.
- Jordan B, Margulies A, Cardoso F, Cavaletti G, Haugnes H, Jahn P, et al. Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO–EONS–EANO clinical practice guidelines for diagnosis, prevention, treatment and follow-up. *Ann Oncol.* 2020;31(10):1306–1319.
- Kerckhove N, Collin A, Condé S, Chaletex C, Pezet D, Balayssac D. Long-term effects, pathophysiological mechanisms, and risk factors of chemotherapy-induced peripheral neuropathies: a comprehensive literature review. *Front Pharmacol.* 2017;8:86.
- Kleckner IR, Jusko TA, Culakova E, Chung K, Kleckner AS, Asare M, et al. Longitudinal study of inflammatory, behavioral, clinical, and psychosocial risk factors for chemotherapy-induced peripheral neuropathy. *Breast Cancer Res Treat.* 2021;189(2):521–32.
- Kolb NA, Smith AG, Singleton JR, Beck SL, Stoddard GJ, Brown S, et al. The association of chemotherapy-induced peripheral neuropathy symptoms and the risk of falling. *JAMA Neurol.* 2016;73(7):860–866.
- Li Y, Tatsui CE, Rhines LD, North RY, Harrison DS, Cassidy RM, et al. Dorsal Root Ganglion Neurons Become Hyperexcitable and Increase Expression of Voltage-Gated T-Type Calcium Channels (Cav3.2) in Paclitaxel-Induced Peripheral Neuropathy. *Pain* 2017, 158, 417–429.
- Krukowski K, Laumet G, Million M, et al. CD8<sup>+</sup> T cells and endogenous IL-10 are required for resolution of chemotherapy-induced neuropathic pain. *PLoS One.* 2014;9(10):e110942.
- Li Y, North RY, Rhines LD, Tatsui CE, Rao G, Edwards DD, et al. DRG voltage-gated sodium channel 1.7 is upregulated in paclitaxel-induced neuropathy in rats and in humans with neuropathic pain. *J Neurosci.* 2018;38:1124–36.
- Li Y, Zhou X, Zhang X, Tan J, Li Y, Peng S. Predictive value of systemic immune inflammation index in chemotherapy-induced peripheral neuropathy in patients with lung cancer. *BMC Cancer.* 2022;22(1):1273.
- Li QX, Shi DJ, Zhang LX, Wang DM, Zhao J, Wang T, et al. Association of body mass and systemic immune-inflammation indices with endocrine therapy resistance in luminal breast cancers. *J Int Med Res.* 2019;47(5):1936–47.
- Liu CC, Lu N, Cui Y, Yang T, Zhao ZQ, Xin WJ. Prevention of paclitaxel-induced allodynia by minocycline: effect on loss of peripheral nerve fibers and infiltration of macrophages in dorsal root ganglia. *Neuropharmacology.* 2020;164:107904.

- Liu J, Shi Z, Bai Y, Liu L, Cheng K. Prognostic significance of systemic immune-inflammation index in triple-negative breast cancer. *Cancer Manag Res.* 2019;11:4471–80.
- Liu XJ, Zhang Y, Liu T, Xu ZZ, Park CK, Berta T, et al. Nociceptive neurons regulate innate and adaptive immunity and neuropathic pain through MyD88 adapter. *Cell Res.* 2014;24(11):1374–7.
- Loprinzi CL, Lacchetti C, Bleeker J, Cavaletti G, Chauhan C, Hertz DL, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update. *J Clin Oncol.* 2020;38:3325–34.
- Meng L, Yang Y, Hu X, Zhang R, Li X. Prognostic value of the pretreatment systemic immune-inflammation index in patients with prostate cancer: a systematic review and meta-analysis. *J Transl Med.* 2023;21(1):79.
- Miltenburg NC, Boogerd W. Chemotherapy-induced neuropathy: a comprehensive survey. *Cancer Treat Rev.* 2014;40(7):872–82.
- Mizrahi D, Park SB, Li T, et al. Hemoglobin, body mass index, and age as risk factors for paclitaxel- and oxaliplatin-induced peripheral neuropathy. *JAMA Netw Open.* 2021;4(2):e2036695.
- Molassiotis A, Cheng HL, Lopez V, et al. Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy. *BMC Cancer.* 2019;19:132.
- Mols F, van de Poll-Franse LV, Vreugdenhil G, Beijers AJ, Kieffer JM, Aaronson NK, et al. Reference data of the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-CIPN20 questionnaire in the general Dutch population. *Eur J Cancer.* 2016;69:28–38.
- Moo TA, Sanford R, Dang C, Morrow M. Overview of breast cancer therapy. *PET Clin.* 2018;13(3):339–54.
- Nicolini G, Monfrini M, Scuteri A. Axonal transport impairment in chemotherapy-induced peripheral neuropathy. *Toxics.* 2015;3(3):322–41.
- Ocean AJ, Vahdat LT. Chemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapies. *Support Care Cancer.* 2004;12(9):619–25.
- Pachman DR, Barton DL, Watson JC, Loprinzi CL. Chemotherapy-induced peripheral neuropathy: prevention and treatment. *Clin Pharmacol Ther.* 2011;90(3):377–87.
- Park SB, Goldstein D, Krishnan AV, Lin CS, Friedlander M, Cassidy J, et al. Chemotherapy-induced peripheral neurotoxicity: a critical analysis. *CA Cancer J Clin.* 2013;63(6):419–37.
- Park SB, Kwok JB, Asher R, Lee CK, Beale P, Selle F, et al. Clinical and genetic predictors of paclitaxel neurotoxicity based on patient-versus clinician-reported incidence and severity of neurotoxicity in the ICON7 trial. *Ann Oncol.* 2017;28(11):2733–40.
- Park HJ. Chemotherapy-induced peripheral neuropathic pain. *Korean J Anesthesiol.* 2014;67(1):4–7.
- Piccart-Gebhart MJ, Pegram MD, Mackey JR, et al. Pharmacokinetics and metabolism of paclitaxel in patients with impaired liver function. *Br J Cancer.* 2005;92(5):946–952.
- Pike CT, Birnbaum HG, Muehlenbein CE, Pohl GM, Natale RB. Healthcare costs and workloss burden of patients with chemotherapy-associated peripheral

- Pratama HA, Wibowo S, Satiti S. Hubungan rasio neutrofil limfosit dengan keparahan chemotherapy induced peripheral neuropathy pada pasien kanker payudara yang mendapat kemoterapi taxane (Tesis). Yogyakarta: Universitas Gadjah Mada; 2017.
- Sekiguchi F, Kawabata A. Role of HMGB1 in chemotherapy-induced peripheral neuropathy. *Int J Mol Sci.* 2020;22(1):367.
- Semple JW, Italiano JE, Freedman J. Platelets and the immune continuum. *Nat Rev Immunol.* 2011;11(4):264–74.
- Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, Macleod MR, et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. *Pain.* 2014;155(12):2461–70.
- Setiawati NC, Wibowo S, Yudiyanita. Pengaruh kadar albumin terhadap derajat keparahan taxane induced peripheral neuropathy pada kanker payudara [thesis]. Yogyakarta: Universitas Gadjah Mada; 2016.
- Simão DADs, Murad M, Martins C, Fernandes VC, Captein KM, Teixeira AL. Chemotherapy-induced peripheral neuropathy: review for clinical practice. *Rev Dor.* 2015;16(3):215–20.
- Singh SK, Krukowski K, Laumet GO, Weis D, Alexander JF, Heijnen CJ, et al. CD8<sup>+</sup> T cell-derived IL-13 increases macrophage IL-10 to resolve neuropathic pain. *JCI Insight.* 2022;7(5):e154194.
- Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. *N Engl J Med.* 2001;344(11):783–92.
- Smith E, et al. Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of methodologies from prospective longitudinal cohort. *BMC Cancer.* 2019;19:530.
- Song SJ, Min J, Suh SY, Jung SH, Hahn HJ, Im SA, et al. Incidence of taxane-induced peripheral neuropathy receiving treatment and prescription patterns in patients with breast cancer. *Support Care Cancer.* 2017;25(7):2241–8.
- Starobova H, Vetter I. Pathophysiology of chemotherapy-induced peripheral neuropathy. *Front Mol Neurosci.* 2017;10:174.
- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* 2021;71(3):209–49.
- Tanabe Y, Hashimoto K, Shimizu C, Hirakawa A, Harano K, Yunokawa M. Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer. *Breast Cancer (Tokyo).* 2013;20(2):132–8.
- Vashistha R, Singh H, Kumar P, Sharma P, Singh G. An up-to-date view of paclitaxel-induced peripheral neuropathy. *J Cancer Res Ther.* 2023;19(6):2020-2028.
- Velasco R, Bruna J. Chemotherapy-induced peripheral neuropathy: an unresolved issue. *Neurologia.* 2010;25(2):116–31.
- Velasco R, Bruna J. Taxane-induced peripheral neurotoxicity. *Toxics.* 2015;3(2):152–69.

- Vincenzi B, Prezza AM, Schiavon G, Spoto C, Addeo R, Catalano V, et al. Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant FOLFOX IV. *Support Care Cancer*. 2013;21(5):1313–9.
- Wang CY, Lin TT, Hu L, Xu CJ, Hu F, Wan L, et al. Neutrophil extracellular traps as a unique target in the treatment of chemotherapy-induced peripheral neuropathy. *EBioMedicine*. 2023;90:104499.
- Wang RT, Zhang JR, Li Y, Liu T, Yu KJ. Neutrophil-lymphocyte ratio is associated with arterial stiffness in diabetic retinopathy in type 2 diabetes. *J Diabetes Complications*. 2015;29(2):245–9.
- Wang X, Han H, Duan Q, Khan U, Hu Y, Yao X. Changes of serum albumin level and systemic inflammatory response in inoperable non-small cell lung cancer patients after chemotherapy. *J Cancer Res Ther*. 2014;10(4):1019–23.
- Wang YT, Kuo LT, Weng HH, Hsu CM, Tsai MS, Chang GH, et al. Systemic immune-inflammation index as a predictor for head and neck cancer prognosis: a meta-analysis. *Front Oncol*. 2022;12:899518.
- Wiranata JA, Astari YK, Ucche M, et al. Predictive factors of chemotherapy-induced peripheral neuropathy in breast cancer: a decision tree model approach. *JCO Glob Oncol*. 2024;(10):e2400160. doi:10.1200/GO.24.00160.
- Wozniak KM, Vornov JJ, Wu Y, Liu Y, Carozzi VA, Rodriguez-Menendez V, et al. Peripheral neuropathy induced by microtubule-targeted chemotherapies: insights into acute injury and long-term recovery. *Cancer Res*. 2018;78:817–29.
- Xu H, Li H, Fan Y, Wang Y, Li Z, Zhou L, Hao X. Analysis of factors influencing chemotherapy-induced peripheral neuropathy in breast cancer patients using a random forest model. *Breast*. 2025 Jun;81:104457.
- Yamanouchi K, Kuba S, Sakimura C, Morita M, Kanetaka K, Kobayashi K, et al. The relationship between peripheral neuropathy induced by docetaxel and systemic inflammation-based parameters in patients with breast cancer. *Anticancer Res*. 2017;37(12):6947–51.
- Yanbing L, Zijun L, Hongbo Z, et al. Relationship between BMI and chemotherapy-induced peripheral neuropathy in cancer patients: a dose-response meta-analysis. *World J Surg Oncol*. 2025;23:77.
- Yang G, Liu P, Zheng L, Zeng J. Novel peripheral blood parameters as predictors of neoadjuvant chemotherapy response in breast cancer. *Front Surg*. 2022;9:1004687.
- Yang R, Chang Q, Meng X, Gao N, Wang W. Prognostic value of systemic immune-inflammation index in cancer: a meta-analysis. *J Cancer*. 2020;11(18):5138–46.
- Yang Y, Zhao B, Gao X, Sun J, Ye J, Li J. Targeting strategies for oxaliplatin-induced peripheral neuropathy: clinical syndrome, molecular basis, and drug development. *J Exp Clin Cancer Res*. 2021;40:331.
- Zajączkowska R, Kocot-Kępska M, Leppert W, Wrzosek A, Mika J, Wordliczek J. Mechanisms of chemotherapy-induced peripheral neuropathy. *Int J Mol Sci*. 2019;20(6):1451.
- Zedan AH, Vilholm OJ. Chemotherapy-induced polyneuropathy: major agents and assessment by questionnaires. *Basic Clin Pharmacol Toxicol*. 2014;115(2):193–200.
- Zhang H, Boyette-Davis JA, Kosturakis AK, Li Y, Yoon SY, Walters ET, et al. Induction of monocyte chemoattractant protein-1 (MCP-1) and its receptor

CCR2 in primary sensory neurons contributes to paclitaxel-induced peripheral neuropathy. *J Pain*. 2013;14(10):1031–1044.

Zhang Y, Sun Y, Zhang Q. Prognostic value of the systemic immune-inflammation index in patients with breast cancer: a meta-analysis. *Cancer Cell Int*. 2020;20:224.

Zhou Y, Guo X, Shen L, Liu K, Sun Q, Wang Y, et al. Predictive significance of systemic immune-inflammation index in patients with breast cancer: a retrospective cohort study. *Onco Targets Ther*. 2023;16:939–60.

Zhu M, Chen L, Kong X, Wang X, Li X, Fang Y, et al. The systemic immune-inflammation index is an independent predictor of survival in breast cancer patients. *Cancer Manag Res*. 2022;14:775–820.